The tuberculosis vaccine market is primarily driven by the high prevalence of tuberculosis globally and the increasing demand for effective vaccines. The development of new vaccines with enhanced efficacy and better safety profiles is also contributing to the growth of the market. However, the lack of awareness and poor healthcare infrastructure in some regions are restraining factors. In addition, the lengthy regulatory approval process and the high cost associated with vaccine development and production are also challenges faced by market players. The key players in the market are focusing on collaborations and partnerships to expand their product portfolio and increase their market share. The COVID-19 pandemic has also affected the market, with disruptions in the supply chain and delays in clinical trials and regulatory approvals. Overall, the Tuberculosis Vaccine Market is expected to grow in the coming years, driven by increasing investments in research and development and the rising demand for effective tuberculosis vaccines.
Leading Companies in the Tuberculosis Vaccine Industry:
GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK) is a British multinational pharmaceutical company founded in 2000. It is headquartered in Brentford, United Kingdom, and operates in over 100 countries worldwide. In October 2020, GSK announced positive results from a phase 2b trial of its tuberculosis vaccine candidate, M72/AS01E, which showed a 50% reduction in the incidence of pulmonary tuberculosis compared to placebo.
Sanofi Pasteur
Sanofi Pasteur is the vaccines division of the French multinational pharmaceutical company Sanofi. It was founded in 1999 and is headquartered in Lyon, France. Sanofi Pasteur operates in over 170 countries worldwide. In December 2021, the company announced the initiation of a phase 3 trial of its tuberculosis vaccine candidate, M72/AS01E2, in HIV-positive adults in sub-Saharan Africa.